Wolverine Trading
SGMO

Wolverine Trading’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Wolverine Trading’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$9.52K Sell
13,600
-2,500
-16% -$1.35K ﹤0.01% 5558
2025
Q2 		$8.71K Sell
16,100
-31,100
-66% -$18.5K ﹤0.01% 4503
2025
Q1 		$38.7K Sell
47,200
-5,300
-10% -$5.61K ﹤0.01% 4478
2024
Q4 		$123K Buy
52,500
+31,400
+149% +$57.4K ﹤0.01% 4731
2024
Q3 		$18.3K Buy
+21,100
New +$15.5K ﹤0.01% 4647
2024
Q2 		– Sell
-10,200
Closed -$6.84K – 5139
2024
Q1 		$6.84K Buy
+10,200
New +$7.4K ﹤0.01% 4376
2022
Q1 		– Sell
-10,200
Closed -$80K – 6329
2021
Q4 		$80K Sell
10,200
-500
-5% -$4.34K ﹤0.01% 5177
2021
Q3 		$98K Sell
10,700
-3,400
-24% -$33.6K ﹤0.01% 5786
2021
Q2 		$165K Buy
14,100
+3,000
+27% +$34K ﹤0.01% 5144
2021
Q1 		$130K Sell
11,100
-50,900
-82% -$686K ﹤0.01% 5313
2020
Q4 		$1.04M Buy
62,000
+11,900
+24% +$139K ﹤0.01% 2326
2020
Q3 		$495K Sell
50,100
-12,600
-20% -$136K ﹤0.01% 2832
2020
Q2 		$550K Sell
62,700
-7,200
-10% -$66.8K ﹤0.01% 2632
2020
Q1 		$454K Sell
69,900
-58,500
-46% -$434K ﹤0.01% 2766
2019
Q4 		$1.05M Buy
128,400
+19,000
+17% +$175K ﹤0.01% 2369
2019
Q3 		$1M Sell
109,400
-6,400
-6% -$71.8K ﹤0.01% 1976
2019
Q2 		$1.25M Sell
115,800
-44,400
-28% -$472K ﹤0.01% 1857
2019
Q1 		$1.53M Sell
160,200
-59,200
-27% -$605K ﹤0.01% 1745
2018
Q4 		$2.38M Buy
219,400
+55,200
+34% +$686K 0.01% 1285
2018
Q3 		$2.78M Buy
164,200
+49,400
+43% +$751K 0.01% 1394
2018
Q2 		$2.18M Hold
114,800
– – 0.01% 1521
2018
Q1 		$2.18M Sell
114,800
-73,100
-39% -$1.56M 0.01% 1521
2017
Q4 		$3.08M Buy
187,900
+53,800
+40% +$800K 0.01% 1192
2017
Q3 		$2.01M Buy
134,100
+49,500
+59% +$547K 0.01% 1317
2017
Q2 		$753K Buy
84,600
+37,900
+81% +$243K ﹤0.01% 2023
2017
Q1 		$219K Buy
46,700
+9,700
+26% +$38.9K ﹤0.01% 3412
2016
Q4 		$113K Buy
37,000
+6,700
+22% +$24.4K ﹤0.01% 4016
2016
Q3 		$138K Sell
30,300
-21,600
-42% -$110K ﹤0.01% 4044
2016
Q2 		$299K Buy
+51,900
New +$331K ﹤0.01% 2798

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wolverine Trading's SGMO Position: Q3 2025 in Review

Wolverine Trading opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q3 2025: 23,799 shares worth $16.7K. The stake represents ﹤0.01% of the portfolio and ranks #5547 among its holdings. This is a return to the name: Wolverine Trading previously reported a position in SGMO as recently as Q1 2025.

Wolverine Trading first reported a position in SGMO in Q2 2016 and has held it in 21 quarters since. The position peaked at $1.69M in Q4 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q3 2025.

  • Wolverine Trading held 23,799 shares of SANGAMO THERAPEUTICS INC worth $16.7K as of Q3 2025.
  • SANGAMO THERAPEUTICS INC was a new Wolverine Trading position in Q3 2025.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5547 holding.
  • Wolverine Trading first reported a position in SANGAMO THERAPEUTICS INC in Q2 2016 and has held it in 21 quarters since.
  • Wolverine Trading's SANGAMO THERAPEUTICS INC position peaked at $1.69M in Q4 2018.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.